A recent phase II clinical trial applying IFN-γ-Dex loaded with MHC class I- and class II-restricted cancer antigens as immunotherapy of NSCLC patients after chemotherapy showed that the expression of MHC class II on Dex correlated with the expression of the NK cell activating NKp30 ligand BCL2-associated athanogene 6 (BAG6) [77]. The gene discussed is BAG6; the disease is cancer.